Clinical Trial Update: Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations [Phase 2]

View source ↗

Summary

Phase II study of crenolanib in relapsed or refractory AML with FLT3 activating mutations has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Acute Myeloid Leukemia

Drugs mentioned

• Crenolanib (Crenolanib)

Snippet

Sponsor: Arog Pharmaceuticals, Inc. | Conditions: Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | Phase 2 | Status: COMPLETED | Results posted: 2024-01-30